Condition: Lupus Nephritis · Sponsor: RemeGen Co., Ltd.
The purpose of this study is to evaluate the safety and efficacy of Telitacicept in adult patients with active lupus nephritis.
This description comes directly from the study's public registry record.
Binghua Xiao · 86-010-58076833 · Binghua.xiao@remegen.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital) | Hefei, Anhui, China | Recruiting |
| Peking University People's Hospital | Beijing, Beijing Municipality, China | Recruiting |
| The First Hospital Affiliated to the Army Medical University | Chongqing, Chongqing Municipality, China | Recruiting |
| The First Affiliated Hospital of Xiamen University | Xiamen, Fujian, China | Recruiting |
| Zhongshan Hospital Affiliated to Xiamen University | Xiamen, Fujian, China | Recruiting |
| Guangdong Provincial People's Hospital | Guangzhou, Guangdong, China | Recruiting |
| The First Affiliated Hospital of Sun Yat-sen University | Guangzhou, Guangdong, China | Recruiting |
| The Third Affiliated Hospital of Sun Yat-sen University | Guangzhou, Guangdong, China | Recruiting |
| Liuzhou Workers' Hospital | Liuzhou, Guangxi, China | Recruiting |
| Guizhou Provincial People's Hospital | Guiyang, Guizhou, China | Recruiting |
| Affiliated Hospital of Hebei University | Baoding, Hebei, China | Recruiting |
| Handan First Hospital | Handan, Hebei, China | Recruiting |
+ 33 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05680480